MiMedx Reports Third Quarter Results

The Marietta-based medical company reports a net loss amid Medicare reimbursement shifts.

Updated on Oct. 28, 2026 in Healthcare

Live Poll

Do you believe larger, established healthcare manufacturers provide better stability for patient wound care?

MiMedx Group reported $62 million in net sales for the third quarter of 2026, marking a 45% decrease compared to the same period in 2025. The company also announced a net loss of $9 million during the quarter.

Why it matters

Changes to Medicare reimbursement policies that took effect in January 2026 significantly hampered the company's wound product sales. These shifts required the business to implement cost-cutting measures and manufacturing efficiencies to navigate the financial downturn.

MiMedx reported $62 million in net sales and a $9 million net loss for the third quarter of 2026. While surgical product sales grew 9%, wound product sales declined 71% compared to the prior year period.

The players

MiMedx Group

This Marietta-based medical company focuses on developing and marketing regenerative medicine products.

U.S. District Court for the Northern District of Georgia

This federal court recently ruled in favor of MiMedx regarding the regulatory classification of the AXIOFILL product.

The details

Despite the overall decline, MiMedx successfully repaid its remaining $17 million term loan balance and secured a $25 million patent license agreement. The company additionally saw a favorable legal development in the U.S. District Court for the Northern District of Georgia regarding its AXIOFILL product.

January 1, 2026: Medicare reimbursement changes took effect.
September 30, 2026: Fiscal third quarter ended.
October 28, 2026: Earnings announcement and conference call held.

Market Landscape

The company's performance is currently defined by the broader impact of the January 1, 2026, Medicare reimbursement changes. This shift forces a strategic pivot toward surgical product growth to offset the instability within the wound care sector.

The company's transition and focus on surgical products may influence the availability of specialized wound care treatments for patients. Consumers should consult their healthcare providers to determine how these organizational changes affect specific treatment plans.

The takeaway

MiMedx is working to stabilize its finances through manufacturing efficiencies and new licensing revenue following a sharp quarterly decline. Investors and patients should monitor how the company adapts to the ongoing impact of federal reimbursement policies on its product portfolio.